OPTIMIZATION OF THERAPY FOR PATIENTS WITH PSORIASIS BASED ON CLINICAL, BIOCHEMICAL AND IMMUNOLOGICAL INDICATORS
Keywords:
psoriasis, treatment, diagnosis, genetics, ecologyAbstract
Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperplasia and impaired immune response. The disease affects approximately 2-3% of the world's population and is associated with marked impairment of quality of life and significant health and social consequences ]20]. The presence of psoriasis in women significantly reduces their self-esteem and quality of life. The pathogenesis of psoriasis is a complex interaction of genetic, environmental, and immunologic factors. Understanding these mechanisms has become the basis for the development of new therapeutic approaches aimed at improving clinical outcomes
References
Armstrong, A.W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA, 323(19), 1945-1960. [doi: 10.1001/jama.2020.4006]
Blauvelt, A., Papp, K.A., Griffiths, C.E.M., et al. (2017). Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 76(3), 407-415. [doi: 10.1016/j.jaad.2016.10.017]
Boehncke, W.H., & Boehncke, S. (2014). Cardiovascular mortality in psoriasis and psoriatic arthritis: Epidemiology, pathomechanisms, and treatment options. Heart International, 9(1), e3. [doi: 10.5301/heartint.5000207]
Boehncke, W.H., & Schön, M.P. (2015). Psoriasis. The Lancet, 386(9997), 983-994. [doi: 10.1016/S0140-6736(14)61909-7]
Finlay, A.Y., & Salek, M.S. (2017). Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 42(1), 8-14. [doi: 10.1111/ced.12873]
Gisondi, P., Del Giglio, M., & Girolomoni, G. (2017). Treatment approaches to moderate to severe psoriasis. International Journal of Molecular Sciences, 18(11), 2425. [doi: 10.3390/ijms18112425]
Gordon, K.B., & Strober, B. (2021). The future of biologic therapy for psoriasis: Secukinumab and ixekizumab. Expert Opinion on Biological Therapy, 21(3), 283-296. [doi: 10.1080/14712598.2021.1869820]
Khujanazarov A., Allamuratov Sh. (2021). HEALTHCARE SYSTEM IN UZBEKISTAN: PROBLEMS AND REFORMS. Bulletin of Science and Practice, 7 (2), 405-410. [https://doi.org/10.33619/2414-2948/63/46]
Kimball, A.B., Jacobson, C., Weiss, S., et al. (2005). The psychosocial burden of psoriasis. American Journal of Clinical Dermatology, 6(6), 383-392. [doi: 10.2165/00128071-200506060-00002]
Lebwohl, M., & Menter, A. (2019). Psoriasis and socioeconomic status: impact on severity, treatment, and outcomes. Journal of the American Academy of Dermatology, 80(6), 1456-1465. [doi: 10.1016/j.jaad.2018.12.064]
Lowes, M.A., Suarez-Fariñas, M., & Krueger, J.G. (2014). Immunology of psoriasis. Annual Review of Immunology, 32, 227-255. [doi: 10.1146/annurev-immunol-032713-120225]
Mannanov A.M., Khaitov K.N. Pediatric skin and venereal diseases. Textbook: Ministry of Higher and Secondary Education of the Republic of Uzbekistan. Tashkent Pediatric Medical Institute; T.: «Iqtisod-Moliya», 2016. 560 pp.
Menter, A., Gelfand, J.M., Connor, C., et al. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 80(4), 1029-1072. [doi: 10.1016/j.jaad.2018.11.057]
Menter, A., Korman, N.J., Elmets, C.A., et al. (2011). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. Journal of the American Academy of Dermatology, 64(4), 563-579. [doi: 10.1016/j.jaad.2010.11.027]
Mrowietz, U., & Kragballe, K. (2014). Definition of treatment goals for moderate to severe psoriasis: A European consensus. Archives of Dermatological Research, 306(1), 61-70. [doi: 10.1007/s00403-013-1407-5]
Nast, A., Spuls, P.I., van der Kraaij, G., et al. (2020). European S3‐Guideline on the systemic treatment of psoriasis vulgaris—Update Apremilast and Secukinumab—EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology, 34(1), 57-82. [doi: 10.1111/jdv.16054]
Olisova, O., Melikova, N., Tashkenbaeva, U., Torchinskiy, N. (2022). Clinical and epidemiological features of psoriasis in the Republic of Uzbekistan. Russian Journal of Skin and Venereal Diseases. 25. 127-132. 10.17816/dv108631.
Papp, K.A., Langley, R.G., Lebwohl, M., et al. (2015). Efficacy and safety of brodalumab for psoriasis after failure of IL-17A inhibition. Journal of the American Academy of Dermatology, 73(3), 439-449. [doi: 10.1016/j.jaad.2015.06.046]
Papp, K.A., Leonardi, C., Menter, A., et al. (2008). Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. New England Journal of Medicine, 366(13), 1181-1189. [doi: 10.1056/NEJMoa1109071]
Parisi, R., Symmons, D.P., Griffiths, C.E., & Ashcroft, D.M. (2013). Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377-385. [doi: 10.1038/jid.2012.339]
Puig, L., & Carrascosa, J.M. (2014). Biologics in psoriasis: A crossroad between guidelines, registries, and new drugs. Current Therapeutic Research, 76(3), 97-101. [doi: 10.1016/j.curtheres.2014.05.002]
Reich, K., Papp, K.A., Blauvelt, A., et al. (2017). Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet, 390(10091), 276-288. [doi: 10.1016/S0140-6736(17)31279-5]
Smith, C.H., Jabbar-Lopez, Z.K., Yiu, Z.Z.N., et al. (2017). British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 177(3), 628-636. [doi: 10.1111/bjd.15665]
Takeshita, J., Grewal, S., Langan, S.M., et al. (2017). Psoriasis and comorbid diseases: Epidemiology. Journal of the American Academy of Dermatology, 76(3), 377-390. [doi: 10.1016/j.jaad.2016.07.064]
